VYGR - Voyager Therapeutics Inc Average Forecast Price
Voyager Therapeutics (VYGR) specializes in innovative therapies for the central nervous system. This price chart reflects the asset's dynamics, where the key indicator equals 14.21. The company maintains pricing power due to its unique methods of transporting genetic material into the brain. Revenue is generated through strategic partnerships and the licensing of AI technologies, which ensures organic growth without the need for mergers and acquisitions.
Analytical breakdowns for Voyager Pharma (VYGR)
- current price and projected stock value:
- market capitalization statistics:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Voyager Therapeutics|VYGR - Long-Term Debt to Capital|Current Liabilities to Capital Voyager Corp|VYGR - Company Total Debt|Debts to Book Capitalization Voyager Pharma|VYGR - Company Long-Term Debt|Company Short-Term Loans and Borrowings Voyager Therapeutics|Immediate Liquidity voyagertherapeutics.com
- earnings and market multiples details:
VYGR - Net Income|Expected Profit Voyager Therapeutics|VYGR - Price to Earnings Ratio|Projected Price to Earnings Ratio Voyager Therapeutics Inc|VYGR - Price/Earnings to Growth Multiple|Company Value to EBITDA Voyager Pharma|VYGR - Operating profit EBITDA|Net earnings per share (EPS TTM) Voyager Therapeutics|VYGR - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year voyagertherapeutics.com|VYGR - Earnings growth in current year|Expected net earnings per share growth next year Voyager Therapeutics
- total revenue and sales volume data:
Summary company analytics:VYGR voyagertherapeutics.com
Voyager Therapeutics (VYGR) is developing CNS gene therapies, leveraging advances from pharma behemoths to optimize capital expenditures and maintain liquidity. The consolidated share price benchmark aggregates one-year investment bank forecasts, transforming market expectations into a dynamic valuation curve of fundamental value. Analyzing this indicator allows for the timely identification of asset overvaluation and the avoidance of investment traps when corporate performance metrics shift.
Competitors of Voyager Therapeutics
Price Target Chart BIIB (biogen.com)|Neurocrine Biosciences, Inc. - Consensus Target|Regencell Bioscience Ltd (RGC) - Average Forecast Price|Axsome Therapeutics Inc - Analyst Consensus Forecast|Analyst Target Range ACADIA Corp (ACAD)|Xenon Pharmaceuticals (XENE) - Price Target Chart|vikingtherapeutics.com - Fair Value Consensus|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Consensus Target PRTA|Price Target Chart ALEC|Price Target Chart Annexon (ANNX)|OMER - Average Forecast Price|Neurogene Corp - Consensus Target|AC Immune Inc (ACIU) - Average Forecast Price|Neumora Therapeutics - Analyst Consensus Forecast|SCLX - Analyst Consensus Forecast|TVGN: Analyst Consensus Forecast|Analyst Target Range Alpha Cognition Inc. ACOG|CGTX (Cognition Therapeutics) - Analyst Consensus Forecast|Average Forecast Price Inhibikase Pharma IKT|Price Target Chart Cassava Sciences, Inc. (SAVA)|ASRT (assertiotx.com) - Fair Value Consensus|Coya Therapeutics - Consensus Target|Fair Value Consensus VTGN|OVID: Consensus Target|Acumen Pharmaceuticals, Inc - Analyst Forecast Prices|CRVO: Analyst Consensus Forecast|Alterity Therapeutics Limited - Fair Value Consensus|CLNN (Clene Inc) - Analyst Consensus Forecast|Average Forecast Price PepGen Corp PEPG|Price Target Chart Jupiter Neurosciences Inc (JUNS)|RLMD (Relmada Corp) - Fair Value Consensus|Analyst Consensus Forecast ANVS (Annovis Bio, Inc.)|Analyst Consensus Forecast Grace Therapeutics Inc GRCE|AIFF - Price Target Chart|Forecast Levels Chart KLTO|NRSN: Analyst Consensus Forecast|Average Forecast Price Reviva Pharmaceuticals, Inc. (RVPH)|Consensus Target MTVA|Analyst Consensus Forecast neuraxis.com|Consensus Target HSDT (Helius Medical)|Analyst Forecast Prices PASG|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|Analyst Median Target Minerva (NERV)|Athira Pharma, Inc. - Analyst Consensus Forecast|addextherapeutics.com (ADXN) - Consensus Target|alzamend.com (ALZN) - Price Target Chart|CYCN - Analyst Median Target|Consensus Target PTIX|Price Target Chart KTTA|Consensus Target CRGT (Cortigent, Inc.)|ATXI - Average Forecast Price|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|Analyst Target Range Cara Therapeutics Inc.|CHRO - Price Target Chart|Fair Value Consensus ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price Target Chart|Broker Consensus Forecast LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Average Forecast Price NKGen Biotech Inc NKGN|Consensus Target NRBO (NeuroBo)|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Price Target Chart Synaptogenix, Inc. SNPX|Fair Value Consensus TRVN|VIGL - Price Target Chart|Average Forecast Price Anew Medical Inc.|CERE (Cerevel) - Consensus Target
